Amgen finally feels the heat from declining market demand; big cuts coming.
Novartis takes a hit on Prexige (COX-2 inhibitor); withdrawn in Australia.
New cancer killers? Electric fields, gene switch. Cool emerging research.
Very lean little biotech (Koronis) pursues a new approach to combating HIV.
GSK and Takeda have to add black box warnings to Avandia and Actos.
J&J taking public blows with Ortho Evra Patch side effects. Also, the company re-affirms its preference for mediation in the ongoing dispute with the American Red Cross over the red cross symbol.
Leave a Reply